Asthma Clinical Trial
— TEXASOfficial title:
Evolution of Physical Activity in Severe Asthmatic Patients Treated With Mepolizumab
Severe asthma is a debilitating condition associated with frequent symptoms, life-threatening exacerbations and corticosteroid side-effects. Exercise limitation due to exercise-induced bronchoconstriction, dynamic lung hyperinflation and comorbidity may be a strong determinant of the disease burden. Mepolizumab is a monoclonal anti-interleukin-5 (IL-5) antibody that reduces the rate of severe exacerbations, asthma symptoms and oral glucocorticoid requirement, and improves quality of life and work productivity in severe eosinophilic asthma. However, its impact on physical activity and exercise tolerance is unknown. We hypothesize that a 6-month treatment with mepolizumab is associated with an improvement in daily life physical activity and exercise tolerance in relation with enhanced ventilatory mechanics.
Status | Recruiting |
Enrollment | 102 |
Est. completion date | July 2, 2025 |
Est. primary completion date | February 2, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Age between 18 and 75 years at the time of inclusion - Asthma diagnosed for at least one year including a history of 1. FEV1 and/or FVC reversibility of more than 12% and than 200 ml documented in the patient's record 2. OR FEV1 variability of more than 20% between two visits 3. OR positive methacholine test - Severe uncontrolled asthma monitored for at least six months in the investigation center with at least two assessments: 1. high-dose of inhaled corticosteroids (ICS >1,000 µg/day of beclometasone equivalent) in combination with another controller at a stable dosage for at least three months 2. ACQ-5 score >1.5 and/or more than two severe exacerbations (i.e exacerbation requiring = 3 days of systemic corticosteroids, hospitalization or admission at the emergency department) in the past year 3. Blood eosinohils =300/mm3 within the 12 past months 4. Decision to introduce mepolizumab according to regulatory approval 5. Patient agreement to receive Mepolizumab - Body mass index (BMI) within the range [18.5 - 35] kg/m2. - Able to give signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol Exclusion Criteria: - Body Mass Index <18.5 or >35 kg/m2 - Active smoker or active smoking during the last 6 months or cumulative > 10 pack-years - All conditions responsible for physical disability (neurological, orthopedic, psychiatric, non-exhaustive list) or other condition limiting exercise in the investigator's opinion - Any chronic respiratory or cardiac pathology which may interfere with the assessment of asthma according to the investigator's opinion - Prior treatment with mepolizumab or benralizumab - Bronchial thermoplasty during the past 12 months - Contraindication to mepolizumab - Non-coverage by the social security insurance - Pregnant, breastfeeding, or lactating women - Patient unable to receive information - Refusal to sign the consent form - Unwillingness or inability to follow the study procedures, in the opinion of the investigator - Person deprived of the liberty Person benefiting from a system of legal protection (guardianship…) |
Country | Name | City | State |
---|---|---|---|
France | Lille University Hospital | Lille |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille | GlaxoSmithKline |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of daily steps | after 6 months of treatment with mepolizumab | ||
Secondary | Time with moderate physical activity (between 3 and 6 METs) and intense activity (>6 METs) | Baseline, at 3 months and at 6 months | ||
Secondary | Percentage of time spent with moderate physical activity (between 3 and 6 METs) and intense activity (>6 METs) | Baseline, at 3 months and at 6 months | ||
Secondary | Ricci and Gagnon questionnaire score • | Ricci and Gagnon questionnaire is Score of physical activity , 9 items, total range score from 6 to 45, higher score indicating a higher level of physical activity | Baseline, at 3 months and at 6 months | |
Secondary | Endurance time during a sub-maximal exercise (80% of maximum load) | Baseline, at 3 months and at 6 months | ||
Secondary | Baseline Dyspnea Index (BDI) | The BDI is an interviewer-administered rating of severity of dyspnea at a single state. It provides a multidimensional measurement of dyspnea based on 3 components It comprises 3 domains (functional impairement, magnitude of task and magnitude of effort) scoring from 0 (very severe) to 4 (no impairment) with a recall of the last two weeks. The total score ranges from 0 to 12, the lower the score, the worse the severity of dyspnea. | Baseline, at 3 months and at 6 months | |
Secondary | Transition Dyspnea Index (TDI) scores | The TDI measures changes in each domain of dyspnea severity from the baseline as established by the BDI. The change is rated by seven grades ranging from -3 (major deterioration) to +3 (major improvement). The total score ranges from - 9 to + 9 | Baseline, at 3 months and at 6 months | |
Secondary | The modified Medical Research Council (mMRC) scale | The mMRC scale is a self-assessed unidimensional scale rating the impact of dyspnea on physical activity in everyday life. The patient chooses the answer that best describes his level of limitation related to dyspnea among 5 proposals. The score is between 0 (absence of dyspnea) to 4 (permanent dyspnea). The MCID considered is 1 unit although data are limited. | Baseline, at 3 months and at 6 months | |
Secondary | Multidimensional Dyspnea Profile (MDP) scores | The MDP questionnaire is an 11-item hetero-questionnaire evaluating both sensory and affective dimensions of dyspnea, respectively the sensation produced by the respiratory stimulus and the emotion associated with this sensation. | Baseline, at 3 months and at 6 months | |
Secondary | ACQ-5 score | The ACQ-5 is a shortened version of the ACQ that assesses asthma symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) omitting the forced expiratory volume in 1 second measurement and short acting beta antagonist use from the original ACQ score. Patients are asked to recall how their asthma has been during the previous week by responding to 5 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-5 score is the mean of the responses. Mean scores of =0.75 indicate well-controlled asthma, scores between 0.75 and <1.5 indicate partly controlled asthma, and a score =1.5 indicates not well controlled asthma . Individual changes of at least 0.5 are considered to be clinically meaningful. | Baseline, at 3 months and at 6 months | |
Secondary | AQLQ score | The Asthma Quality of Life Questionnaire (AQLQ) is a 32-item, 4-domain instrument that can either be self- or interviewer-administered. The recall-time is two weeks. The four domains covered are: (i) symptoms (11 items), (ii) activity limitation (12 items, 5 of which are individualized), (iii) emotional function (5 items), and (iv) environmental exposure (4 items). Each item is ranked by the patient using a 7-point Likert scale ranging from 1 (severely impaired) to 7 (not impaired at all). Scores range from 1 to 7, higher scores indicate better quality of life and a minimally important difference (for overall scores and for each sub-domain) has been established at 0.5. | Baseline, at 3 months and at 6 months | |
Secondary | Hospital Anxiety and Depression scores (HADS) | Depressive symptoms will be assessed using The Hospital Depression and Anxiety Scale.The scale allows to detect anxiety and depression using 14 items rated from 0-3. | Baseline, at 3 months and at 6 months | |
Secondary | Respiratory capacity by Spirometry | Baseline, at 3 months and at 6 months | ||
Secondary | Respiratory capacity by plethysmography | Baseline, at 3 months and at 6 months | ||
Secondary | Forced inspiratory by Spirometry | Baseline, at 3 months and at 6 months | ||
Secondary | Ventilatory function by Spirometry | Baseline, at 3 months and at 6 months | ||
Secondary | Forced oscillation by impulse oscillometry (the Tremoflo ® oscillometry system) | Baseline, at 3 months and at 6 months | ||
Secondary | Frequency of serious and non-serious side effects | Baseline, at 3 months and at 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|